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Abstract 
Background: Recent analyses in a registry of hypertensive patients suggested that preceding left ventricular (LV) 
hypertrophy (LVH) and/or carotid atherosclerosis are associated with incident type 2 diabetes, independent of con-
founders. We assess the relation between prevalent cardio-renal target organ damage (TOD) and subsequent incident 
type 2 diabetes in a population-based study with high prevalence of obesity.
Methods: We selected 2887 non-diabetic participants from two cohorts of the Strong Heart Study (SHS). Clinical 
exam, laboratory tests and echocardiograms were performed. Adjudicated TODs were LVH, left atrium (LA) dilatation, 
and high urine albumin/creatinine ratio (UACR). Multivariable logistic regression models were used to identify vari-
ables responsible for the association between initial TODs and incident diabetes at 4-year follow-up (FU).
Results: After 4 years, 297 new cases of diabetes (10%) were identified, 216 of whom exhibited baseline impaired 
fasting glucose (IFG, 73%, p < 0.0001). Participants developing type 2 diabetes exhibited higher inflammatory mark-
ers, fat-free mass and adipose mass and higher prevalence of initial LVH and LA dilatation than those without (both 
p < 0.04). In multivariable logistic regression, controlling for age, sex, family relatedness, presence of arterial hyperten-
sion and IFG, all three indicators of TOD predicted incident diabetes (all p < 0.01). However, the effects of TOD was 
offset when body fat and inflammatory markers were introduced into the model.
Conclusions: In this population-based study with high prevalence of obesity, TOD precedes clinical appearance of 
type 2 diabetes and is related to the preceding metabolic status, body composition and inflammatory status.
Trial registration Trial registration number: NCT00005134, Name of registry: Strong Heart Study, URL of registry: https://
clinicaltrials.gov/ct2/show/NCT00005134, Date of registration: May 25, 2000, Date of enrolment of the first participant 
to the trial: September 1988
Keywords: Arterial hypertension, Left ventricular hypertrophy, Left atrial dilatation, Target organ damage, Body 
composition, Inflammation
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Background
Similar to arterial hypertension and obesity, type 2 dia-
betes mellitus is associated with target organ damage 
(TOD) [1–3]. However, the sequence between major 
CV risk factor and TOD has been brought into question 
by evidence that sometimes TOD precedes the clinical 
appearance of the disease that is thought to cause it. This 
potential reverse causation has also been postulated for 
arterial hypertension and for the possibility to optimally 
control blood pressure by therapy [4, 5].
More recently, analyses performed in the hypertensive 
population of the Campania Salute Network (CSN) reg-
istry demonstrated that LV hypertrophy and/or carotid 
atherosclerosis are predictors of incident type 2 diabetes 
[6], independent of a number of confounders, includ-
ing age, metabolic syndrome, family history of diabetes, 
duration of hypertension, and number and type of anti-
hypertensive medications. While in the case of hyper-
tension, masked hypertension and non-dipping pattern 
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due to obstructive sleep apnoea, could help explain why 
LV hypertrophy appears before clinical manifestation of 
hypertension detected in the doctor’s office, in the case of 
type 2 diabetes a clear explanation is more difficult. The 
reported temporal sequence between TOD and clinical 
presentation of DM was possibly attributed to risk fac-
tors both affecting the CV system and leading to type 2 
diabetes, to which LV hypertrophy and/or carotid ath-
erosclerosis may be more sensitive, potentially consistent 
with the postulated possibility of a vascular origin of type 
2 diabetes [6].
At present, the generalizability of the findings of the 
Campagna Salute Network hypertensive registry to 
unselected populations cohorts has not been evaluated. 
Accordingly, this analysis has been designed to evalu-
ate the relation between prevalent TOD and subsequent 
incident type 2 diabetes in the population of the Strong 
Heart Study (SHS), and to verify whether conditions 
associated to pre-diabetes help explain the association.
Methods
Population
The SHS is a population-based cohort-study of CV 
risk factors and disease in American Indians origi-
nally from 13 communities, as extensively previously 
described [7, 8], with follow-up examinations of the 
original SHS cohort approximately 4 and 8  years after 
the 1st SHS exam in 1989–1992. During the 2nd exam, 
the SHS cohort members underwent also standard 
Doppler-echocardiography. The 4th SHS exam, in 2001–
2003, enrolled members of large multi-generation fami-
lies [Strong Heart Family Study (SHFS)], who underwent 
echocardiography [9, 10].
After exclusion of type 2 diabetes participants from 
the SHS and SHFS cohorts, and withdrawal by one com-
munity of consent to use their data, a sub-cohort of 
3585 non diabetic participants remained. From the 4th 
SHS exam, we also excluded 200 participants, who were 
already included in the present analysis as participants 
of the 2nd SHS exam. Thus, the study population com-
prised 3385 participants (1963 or 58% women). Death 
occurred in 354 participants before the 4-year follow-up. 
Among the remaining 3031 participants, follow-up data 
were available in 2887 participants (92%, 1721 women or 
60%). Figure 1 displays the steps for selection of the study 
population.
Clinical examination, laboratory tests and definitions
Detailed descriptions of the study design and methods of 
the SHS and SHFS have previously been reported [7–10]. 
Obesity was classified as BMI ≥30 kg/m2. Waist circum-
ference was used as an indicator of central adiposity, 
using sex-specific cut-points [11]. Arterial hypertension 
was defined by BP ≥140/90 mmHg or current antihyper-
tensive treatment.
Fat-free mass and adipose body mass were estimated 
by using an RJL bioelectric impedance meter (model 
B14101; RJL Equipment Co.), as previously reported [12]. 
Fig. 1 Selection of the study population from the original cohort of non-diabetic participants to the Strong Heart Study and the Strong Heart Fam-
ily Study
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Equations to estimate fat-free mass (FFM) in kg, based 
on total body water, had been previously validated in the 
American Indian population [13].
Fasting plasma glucose, lipid profile and other labora-
tory variables were measured by standard methods, as 
previously reported [7, 8]. Type 2 diabetes was defined as 
fasting glucose ≥126 mg/dL or use of antidiabetic treat-
ment [14]. Impaired fasting glucose (IFG) was defined as 
a fasting glucose  >100  mg/dL [11], whereas fasting glu-
cose ≤100 mg/dL was defined as normal fasting glucose 
(NFG).
Glomerular filtration rate (GFR) was estimated by the 
simplified Modification of Diet in Renal Disease formula 
[15]. Urinary albumin excretion was measured on a sin-
gle spot urine sample and was expressed in relation to 
grams of urinary creatinine (uAlb/Crea). The ratio uAlb/
Crea was also categorized based on the distribution in 
initially non-diabetic participants in this study, using the 
75th percentile of the distribution (i.e. 13  g/mg) as cut 
point.
Echocardiographic measures
Echocardiograms were performed using phased-array, 
commercially available echocardiographs, with M-mode, 
two-dimensional and Doppler capabilities, and read off 
line using working stations equipped with frame-grabber 
to measure on analog stop-frame images, as previously 
reported in detail [16, 17]. From left ventricular (LV) 
internal dimension and wall thicknesses, LV mass (LVM) 
was calculated using an autopsy-validated formula [18] 
and normalized by height to the allometric power of 2.7 
(LVMi) [19]. LV hypertrophy (LVH) was defined using 
the population specific partition values of 47.2 g/m2.7 for 
both men and women [19]. In the SHS, this cut-point 
maximized the population risk attributable to LVH, 
compared to sex-specific approaches. LV geometry was 
assessed by relative wall thickness (RWT) normalized to 
an age of 46 years (RWTa), as previously suggested [20]. 
LV concentricity was defined as RWTa greater than 0.41 
[20]. Analysis of reliability of echocardiographic LV mass 
yielded an intraclass coefficient of 0.93 in this laboratory 
(p < 0.001) [21].
Left atrial (LA) volume (LAv), in mL was estimated 
using a recently-validated equation derived from the lin-
ear antero-posterior dimension (LAd, in cm), measured 
in long-axis parasternal view [22]. Thus:
LAv was normalized for height in meters raised to 
the second power, based on a recent evidence provided 
by an European epidemiologic study [23]. From this 
study, the sex-specific partitions of  >19.4  mL/m2 for 
men and >16.6 mL/m2 for women were adopted, which 
LAv = 2.32× LAd
2.07
provide high sensitivity and specificity for detection of 
LA dilatation [22].
Outcome variables
The outcome variable of this study was incident type 2 
diabetes defined as fasting glucose ≥126  mg/dL or tak-
ing oral antidiabetic medications. Censoring for diabetes 
was done after 4 years (exams 3 and 5, for the SHS origi-
nal cohort and for the SHFS, respectively). The markers 
of TOD evaluated as predictors of incident diabetes were 
LV hypertrophy, LA dilatation and high uAlb/Crea.
Statistics
Data were analyzed using IBM-SPSS 23.0 and expressed 
as mean ±  standard deviation or proportion in the Chi 
square distribution. Indicator variables were included for 
the Arizona, South/North Dakota and Oklahoma field 
centers. Because in this population, including members 
of the SHFS cohort, the level of family relatedness was 
high, we adjusted analysis for a standard kinship coeffi-
cient, based on the level of relatedness within family, as 
previously reported [24]. Continuous baseline variables 
were compared between groups with or without incident 
diabetes, using 2-factor ANCOVA, adjusting for baseline 
glucose status (i.e. NFG or IFG), and family relatedness. 
Skewed variables were logarithmically transformed to 
be analysed with parametric statistics, and are expressed 
as median and interquartile range. To verify whether the 
markers of TOD retained their effect on incident diabe-
tes, sequential multivariable logistic regression models 
were implemented for each TOD marker, to identify con-
founders (if any) that could help explain its association 
with incident type 2 diabetes. Because among the vari-
ables of interest, we found about 2% of missing values, 
with no variables exceeding more than 10% of missing 
values, multiple imputation was adopted, using the SPSS 
automatic imputing algorithm [25, 26].
Results
Of the 2887 participants, 1825 presented with nor-
mal fasting glucose (NFG, 60% women) and 1062 (57% 
women) with impaired fasting glucose (IFG).
At the censoring time, 4 years after the initial examina-
tion, 297 new cases of type 2 diabetes (10% of the study 
population) were identified, 216 of whom exhibited base-
line impaired fasting glucose (73%, p  <  0.0001). At the 
initial exam, hypertension was present in 30% of the nor-
mal fasting glucose (NFG) sub-population and in 48% of 
participants with IFG (p  <  0.0001). Even more marked 
was the difference in central fat distribution (55% in NGT 
and 74% in IFG, p < 0.0001).
The following analyses were carried out in the censored 
subpopulation at follow-up. Incident type 2 diabetes was 
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associated with initial IFG, greater prevalence of obesity, 
substantial prevalence of central fat distribution, whereas 
the difference in prevalent arterial hypertension was not 
significant.
Participants developing type 2 diabetes also exhibited 
higher blood pressure, heart rate, BMI and waist circum-
ference, fasting insulin and HOMA-R index, and more 
abnormal lipid profile (lower levels of HDL-cholesterol 
and higher triglycerides) than those remaining in the 
non-diabetic range. No between-group difference was 
detected in age, sex distribution and kidney function. 
Fibrinogen and PAI-1, the inflammatory markers tested 
in this analysis, were significantly higher in participants 
developing type 2 diabetes than in those remaining in the 
non-diabetic range. Both fat-free mass and adipose mass 
were also greater in participants developing type 2 diabe-
tes (Table 1).
LV chamber dimension and mass and estimated LA 
volume were greater in participants developing type 
2 diabetes during follow-up, who also exhibited a ten-
dency toward more concentric LV geometry (Table  1). 
Participants developing type 2 diabetes had a twofold 
higher prevalence of initial LVH than those remaining 
with plasma glucose in the non-diabetic range (23 vs. 
13%, OR = 2.04 [95% CI = 1.51–2.77], p < 0.0001). Simi-
larly, the prevalence of initial LA dilatation was twofold 
greater in participants with incident type 2 diabetes (8 vs. 
4%, OR = 2.23 [95°CI = 1.39–3.58], p < 0.001). The ratio 
uAlb/Crea did not exhibit significant difference between 
the two subpopulations, but participants developing type 
2 diabetes were 1.5-fold more likely to have values greater 
than the 75th percentile of the distribution (32 vs. 23%, 
OR = 1.55 [1.19–2.01], p < 0.001).
Multivariable logistic regression models were run to 
determine the possible factors responsible for the asso-
ciation between each indicator of initial TOD and inci-
dent type 2 diabetes at 4 years of follow-up. Figure 2 and 
Table  2 show the odds ratios and corresponding 95% 
Table 1 Clinical and echocardiographic characteristics of participants remaining non-diabetic and those developing dia-
betes
BP blood pressure, GFR glomerular filtration rate, LV left ventricle, LVDD LV diastolic dimension, LA left atrium, LAV LA volume
* Adjusted for initial glucose status and kinship coefficients (to account for family relatedness)
† After log transformation. Medians and interquartile range are displayed
a Normalized to age 46
b Indexed for height to the second power
No incident diabetes (n = 2590) Incident diabetes (n = 297) p≤*
Age (years) 44 ± 17 47 ± 15 0.101
Sex (% women) 60 61 0.662
Systolic BP (mmHg) 122 ± 17 127 ± 17 0.02
Diastolic BP (mmHg) 75 ± 11 78 ± 11 0.003
Heart rate (bpm) 68 ± 11 70 ± 11 0.02
Body mass index (kg/m2) 30 ± 7 35 ± 7 0.0001
Waist circumference (cm) 100 ± 16 113 ± 16 0.0001
GFRMDRD (mL/min/1.73 m
2) 92 [78–108] 92 [79–109] 0.178†
Cholesterol (mg/dL) 187 ± 37 187 ± 39 0.370
HDL-c (mg/dL) 50 ± 15 44 ± 14 0.0001
Triglycerides (mg/dL) 120 [86–171] 147 [107–196] 0.002†
Fasting glucose (mg/dL) 96 ± 13 109 ± 25 0.0001
Fasting insulin (mIU/mL) 11 [7–17] 21 [13–31] 0.0001†
HOMA-R 2.6 [1.6–4.2] 5.2 [3.4–8.3] 0.0001†
Fibrinogen (mg/dL) 347 [304–399] 367 [322–427] 0.01†
PAI-1 (mg/dL) 42 [26–65] 58 [38–93] 0.01†
Fat-free mass (kg) 53 ± 12 59 ± 14 0.04
Adipose mass (kg) 35 ± 10 40 ± 8 0.0001
LVDD index (cm/m) 3.09 ± 0.25 3.16 ± 0.29 0.008
LV mass index (g/m2.7) 38.0 ± 8.8 42.2 ± 10.3 0.0001
Relative wall  thicknessa 0.32 ± 0.05 0.33 ± 0.04 0.006
LAV index (mL/m2)b 11.4 ± 3.0 13.1 ± 3.0 0.0001
Ejection fraction (%) 63 ± 5 64 ± 5 0.2
Urinary albumin/creatinine 6.55 [4.22–12.08] 8.32 [4.95–16.56] 0.152†
Page 5 of 9de Simone et al. Cardiovasc Diabetol  (2017) 16:64 
confidence intervals for LVH, LA dilatation and high 
albumin/creatinine ratio in 4 sequential models forcing 
incremental sets of potential confounders. In the first 
models, all three indicators of TOD were associated with 
incident type 2 diabetes, independently of age, sex and 
family relatedness (all p  <  0.009). This association was 
not modified when the effect of arterial hypertension 
was also considered, but was attenuated when initial glu-
cose status entered the model (all p < 0.05). The residual 
effects of LVH, LA dilatation and high urinary albumin/
creatinine excretion were substantially offset when body 
fat and central fat distribution were introduced into the 
model (Table  2). Forcing in the last model markers of 
inflammation did not modify further the impact of TOD 
on incident type 2 diabetes (ORs were 1.2, p = 0.283 for 
LVH; 1.42, p = 0.183 for LA dilatation; 1.24, p = 0.141 for 
high uAlb/Crea). 
To obtain a phenotypical profile of individuals at high 
risk of developing type 2 diabetes, in a further analysis, 
we used all variables of model 4 (as in Fig. 2 and Table 2), 
also adding inflammatory markers in a stepwise build-
ing model. Table 3 displays that the phenotype at risk of 
type 2 diabetes was a male, with impaired fasting glucose, 
abnormal body composition (increasing by 6% risk of 
type 2 diabetes for each kg of adipose mass contributing 
Fig. 2 Risk of development of diabetes (expressed as OR and 95% of confidence interval) based on three indicator of target organ damage: LV 
hypertrophy (white circles), LA dilatation (grey circles) and high urinary albumin/creatinine excretion (black circle). All p value <0.05 except in Model 4
Table 2 Odds of 4-year incident type 2 diabetes mellitus in relation to specific markers of cardio-renal TOD
Model 1 adjusted for age, sex, family relatedness, field center
Model 2 adjusted for Model 1 + arterial hypertension
Model 3 adjusted for Model 2 + impaired fasting glucose
Model 4 adjusted for Model 3 + Body fat and visceral adiposity
LV hypertrophy LA dilatation High urinary albumin/creatinine
OR 95% CI p≤ OR 95% CI p≤ OR 95% CI p≤
Model 1 1.76 1.29 −2.39 0.0001 1.94 1.20 −3.15 0.007 1.43 1.09 −1.86 0.009
Model 2 1.77 1.30 −2.41 0.0001 1.96 1.21 −3.18 0.007 1.44 1.10 −1.88 0.007
Model 3 1.55 1.12 −2.14 0.008 1.86 1.13 −3.09 0.02 1.32 1.01 −1.74 0.048
Model 4 1.18 0.85 −1.64 0.322 1.41 0.85 −2.35 0.187 1.29 0.97 −1.70 0.077
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to his body weight) and high levels of inflammatory 
markers, with no significant effect of central adiposity.
To verify the cofactors that influence the impact of 
central fat distribution on incident type 2 diabetes, we 
built a sequential logistic model forcing central fat dis-
tribution as the first predictor of incident type 2 diabe-
tes, adjusting for age, sex and relatedness (OR  =  3.68 
[2.2–5.19], p < 0.0001). In a second step, LVH, impaired 
fasting glucose and amount of body fat were also forced, 
and the significant association of central fat distribution 
with incident type 2 diabetes was attenuated (OR = 1.52 
[1.01–2.29], p  <  0.05). Finally, inflammatory markers 
(PAI-1 and fibrinogen) were added in the model with 
the consequent drop of statistical impact of central fat 
distribution on probability of incident type 2 diabetes 
(OR = 1.35 [0.89–2.07], p < 0.155).
Discussion
In the present study, conducted in an unselected cohort 
of non-diabetic American Indians, cardiac and renal 
TOD, generally attributable to type 2 diabetes, preceded 
the clinical appearance of the disease. This finding con-
firms, on a population-based scale, findings reported in 
the observational hypertensive registry of the Campania 
Salute Network [6]. However, the analysis performed in 
the SHS cohort at least in part clarifies the possible mech-
anisms of this apparent reverse-causality association.
Cardio‑renal TOD and incident diabetes
Similar to what reported in the Campania Salute Net-
work [6], in the SHS cohort, cardio-renal TOD was asso-
ciated with 4-year incident type 2 diabetes, independent 
of age, sex, family relatedness and, most important, arte-
rial hypertension, but the metabolic phenotype preced-
ing the clinical manifestation of type 2 diabetes could 
largely explain the temporal association between TOD 
and incident type 2 diabetes. This metabolic phenotype 
included insulin resistance, amount of body fat and vis-
ceral adiposity. That type 2 diabetes can be predicted by 
this unfavorable metabolic phenotype is not surprising 
[27], but it is of note that LV hypertrophy, LA dilatation 
and, to some extent, proteinuria precede development of 
the disease.
We have already shown that these abnormalities were 
present in the adolescent population of the SHFS with 
IFG [24]. The sequential logistic model we run in the pre-
sent analysis largely demonstrate that at the basis of the 
evidence of TOD preceding detection of type 2 diabetes 
there are metabolic abnormalities with high potential to 
have impact on the CV system. This observation is well 
fitting with cross-sectional and longitudinal analyses 
demonstrating that substantial CV risk attributable to 
type 2 diabetes is sustained by the coexisting metabolic 
abnormalities, often clustered in the metabolic syndrome 
[28–30]. However, the evidence we provide is specific 
for cardio-renal TOD, and may not be extrapolated to 
the vascular bed, a district in which the atherosclerotic 
evolution is more accelerated in type 2 diabetes than in 
metabolic syndrome without diabetes [31]. This athero-
sclerotic evolution is also responsible for specific func-
tional alterations in diabetes, such as increased arterial 
stiffness [32].
Influence of arterial hypertension
In multivariable logistic regression, arterial hyperten-
sion did not influence the relation between cardio-renal 
TOD and incident type 2 diabetes, though the prevalence 
of hypertension in this population was high (40%). This 
finding is fitting with other observations from the SHS 
and other epidemiological studies [33–35], demonstrat-
ing disagreement between evolution of TOD and blood 
pressure.
It is also of note that the phenotype at risk of type 
2 diabetes emerging from our analysis is not substan-
tially different from that associated with 8-year incident 
hypertension in SHS participants with NFG and opti-
mal blood pressure at the initial observation [36]. In that 
study, central fat distribution was a key factor also for 
incident hypertension, and, interestingly, type 2 diabetes 
detected after 4 years was independently associated with 
Table 3 Significant predictors of  incident diabetes (by backward logistic regression, including  all variables displayed 
in Fig. 2
b Wald p≤ OR 95% Conf. interv.
Female sex −0.77 16.30 0.0001 0.47 0.32 −0.67
Impaired fasting glucose 1.45 99.73 0.0001 4.25 3.20 −5.65
Body fat (kg) 0.06 33.84 0.0001 1.06 1.04 −1.09
Fibrinogen  (log10 [mg/dL]) 1.98 6.81 0.009 7.18 1.63 −31.53
PAI-1  (log10 [mg/dL]) 0.93 14.49 0.0001 2.54 1.57 −4.10
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2.6-fold greater risk of being hypertensive at the censor-
ing time after 8 years follow-up. Considering all together 
these findings strongly indicate that both type 2 diabetes 
and, to some extent, hypertension share a common risk 
phenotype.
Inflammation
The present analysis also suggests a strong role of central 
fat distribution-related inflammation in the development 
of type 2 diabetes [37]. Inflammation was not considered 
in our analysis on incident hypertension, in which, in fact, 
central fat distribution was a critical predicting factor [36], 
as it was in the present logistic model before entering the 
inflammatory markers. The link between type 2 diabetes 
and inflammation has been reported in other studies [38].
Limitations
In the present study, we adopted the simplest possible 
diagnostic criterion for DM, according to ADA recom-
mendations. However, a further in-depth screening, 
using 2  h OGTT could have revealed more prevalent 
diabetes, and could even better refine the selection of the 
study population. However, though it could be appropri-
ate, the current recommendations do not require further 
diagnostic tests for subjects classified in the range of 
impaired fasting glucose and our criterion is more adher-
ent to the present clinical practice.
In the SHS, arterial hypertension has been detected 
using office and not ambulatory BP monitoring. Because 
the high prevalence of central obesity and IFG, masked 
hypertension might not be rare in the SHS participants 
[39]. Thus, we cannot rule out the possibility that the 
diagnosis of hypertension at the time of initial examina-
tion was underestimated.
In our analysis, sex has been used as a covariate, 
because the lack of adequate power to run sex-spe-
cific analyses. However, sex-differences in the relation 
between both cardio-renal and vascular TOD and inci-
dent diabetes might be relevant. The progression of 
vascular TOD seems to be more accentuated in women 
than in men [32, 40], and the prevalence of cardiac TOD 
is higher in women, especially in the presence of central 
obesity and abnormal body composition [12, 41], both 
factors predicting incident diabetes.
Conclusions
In this population-based study, we demonstrated that 
cardio-renal TOD generally attributable to type 2 dia-
betes precedes the clinical detection of the disease, but 
is substantially related to the metabolic status preced-
ing diabetes including IFG, body fat accumulation and 
inflammation.
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